• Je něco špatně v tomto záznamu ?

European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies

G. Deuschl, A. Antonini, J. Costa, K. Śmiłowska, D. Berg, JC. Corvol, G. Fabbrini, J. Ferreira, T. Foltynie, P. Mir, A. Schrag, K. Seppi, P. Taba, E. Ruzicka, M. Selikhova, N. Henschke, G. Villanueva, E. Moro

. 2022 ; 37 (7) : 1360-1374. [pub] 20220706

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22025352

BACKGROUND AND PURPOSE: This update of the treatment guidelines was commissioned by the European Academy of Neurology and the European section of the Movement Disorder Society. Although these treatments are initiated usually in specialized centers, the general neurologist should know the therapies and their place in the treatment pathway. METHODS: Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess the spectrum of approved interventions including deep brain stimulation (DBS) or brain lesioning with different techniques (radiofrequency thermocoagulation, radiosurgery, magnetic resonance imaging-guided focused ultrasound surgery [MRgFUS] of the following targets: subthalamic nucleus [STN], ventrolateral thalamus, and pallidum internum [GPi]). Continuous delivery of medication subcutaneously (apomorphine pump) or through percutaneous ileostomy (intrajejunal levodopa/carbidopa pump [LCIG]) was also included. Changes in motor features, health-related quality of life (QoL), adverse effects, and further outcome parameters were evaluated. Recommendations were based on high-class evidence and graded in three gradations. If only lower class evidence was available but the topic was felt to be of high importance, clinical consensus of the guideline task force was gathered. RESULTS: Two research questions have been answered with eight recommendations and five clinical consensus statements. Invasive therapies are reserved for specific patient groups and clinical situations mostly in the advanced stage of Parkinson's disease (PD). Interventions may be considered only for special patient profiles, which are mentioned in the text. Therapy effects are reported as change compared with current medical treatment. STN-DBS is the best-studied intervention for advanced PD with fluctuations not satisfactorily controlled with oral medications; it improves motor symptoms and QoL, and treatment should be offered to eligible patients. GPi-DBS can also be offered. For early PD with early fluctuations, STN-DBS is likely to improve motor symptoms, and QoL and can be offered. DBS should not be offered to people with early PD without fluctuations. LCIG and an apomorphine pump can be considered for advanced PD with fluctuations not sufficiently managed with oral treatments. Unilateral MRgFUS of the STN can be considered for distinctly unilateral PD within registries. Clinical consensus was reached for the following statements: Radiosurgery with gamma radiation cannot be recommended, unilateral radiofrequency thermocoagulation of the pallidum for advanced PD with treatment-resistant fluctuations and unilateral radiofrequency thermocoagulation of the thalamus for resistant tremor can be recommended if other options are not available, unilateral MRgFUS of the thalamus for medication-resistant tremor of PD can be considered only within registries, and unilateral MRgFUS of the pallidum is not recommended. CONCLUSIONS: Evidence for invasive therapies in PD is heterogeneous. Only some of these therapies have a strong scientific basis. They differ in their profile of effects and have been tested only for specific patient groups. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Campus Neurológico Torres Vedras Portugal

Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas Madrid Spain

Cochrane Response London UK

Departamento de Medicina Facultad de Medicina Universidad de Sevilla Seville Spain

Department Human Neurosciences Sapienza University of Rome Rome Italy

Department of Clinical and Movement Neurosciences Institute of Neurology London UK

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czechia

Department of Neurology and Neurosurgery Institute of Clinical Medicine University of Tartu Tartu Estonia

Department of Neurology UKSH Kiel Campus Christian Albrechts University Kiel Germany

Division of Neurology Grenoble Grenoble Institute of Neurosciences Grenoble Alpes University Grenoble France

Faculdade de Medicina da Universidade de Lisboa Lisbon Portugal

Faculdade de Medicina Universidade de Lisboa Lisbon Portugal

Institut du Cerveau Paris Brain Institute Assistance Publique Hôpitaux de Paris Pitié Salpêtrière Hospital Department of Neurology Centre d'Investigation Clinique Neurosciences Sorbonne Université Paris France

Institute of Neurology University Clinic London London UK

Instituto de Medicina Molecular João Lobo Antunes Lisbon Portugal

IRCCS Neuromed Rome Italy

Klinik f Neurologie Medizinische Universität Innsbruck Innsbruck Austria

Parkinson and Movement Disorders Unit Department of Neuroscience University of Padua Padua Italy

Southmead Hospital Bristol Brain Centre Bristol UK BS10 5NB

Tartu University Hospital Tartu Estonia

Unidad de Trastornos del Movimiento Servicio de Neurología y Neurofisiología Clínica Instituto de Biomedicina de Sevilla Hospital Universitario Virgen del Rocío Universidad de Sevilla Seville Spain

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025352
003      
CZ-PrNML
005      
20221031100819.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/mds.29066 $2 doi
035    __
$a (PubMed)35791767
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Deuschl, Günther $u Department of Neurology, UKSH-Kiel Campus, Christian-Albrechts-University, Kiel, Germany $1 https://orcid.org/0000000241769196
245    10
$a European Academy of Neurology/Movement Disorder Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies / $c G. Deuschl, A. Antonini, J. Costa, K. Śmiłowska, D. Berg, JC. Corvol, G. Fabbrini, J. Ferreira, T. Foltynie, P. Mir, A. Schrag, K. Seppi, P. Taba, E. Ruzicka, M. Selikhova, N. Henschke, G. Villanueva, E. Moro
520    9_
$a BACKGROUND AND PURPOSE: This update of the treatment guidelines was commissioned by the European Academy of Neurology and the European section of the Movement Disorder Society. Although these treatments are initiated usually in specialized centers, the general neurologist should know the therapies and their place in the treatment pathway. METHODS: Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess the spectrum of approved interventions including deep brain stimulation (DBS) or brain lesioning with different techniques (radiofrequency thermocoagulation, radiosurgery, magnetic resonance imaging-guided focused ultrasound surgery [MRgFUS] of the following targets: subthalamic nucleus [STN], ventrolateral thalamus, and pallidum internum [GPi]). Continuous delivery of medication subcutaneously (apomorphine pump) or through percutaneous ileostomy (intrajejunal levodopa/carbidopa pump [LCIG]) was also included. Changes in motor features, health-related quality of life (QoL), adverse effects, and further outcome parameters were evaluated. Recommendations were based on high-class evidence and graded in three gradations. If only lower class evidence was available but the topic was felt to be of high importance, clinical consensus of the guideline task force was gathered. RESULTS: Two research questions have been answered with eight recommendations and five clinical consensus statements. Invasive therapies are reserved for specific patient groups and clinical situations mostly in the advanced stage of Parkinson's disease (PD). Interventions may be considered only for special patient profiles, which are mentioned in the text. Therapy effects are reported as change compared with current medical treatment. STN-DBS is the best-studied intervention for advanced PD with fluctuations not satisfactorily controlled with oral medications; it improves motor symptoms and QoL, and treatment should be offered to eligible patients. GPi-DBS can also be offered. For early PD with early fluctuations, STN-DBS is likely to improve motor symptoms, and QoL and can be offered. DBS should not be offered to people with early PD without fluctuations. LCIG and an apomorphine pump can be considered for advanced PD with fluctuations not sufficiently managed with oral treatments. Unilateral MRgFUS of the STN can be considered for distinctly unilateral PD within registries. Clinical consensus was reached for the following statements: Radiosurgery with gamma radiation cannot be recommended, unilateral radiofrequency thermocoagulation of the pallidum for advanced PD with treatment-resistant fluctuations and unilateral radiofrequency thermocoagulation of the thalamus for resistant tremor can be recommended if other options are not available, unilateral MRgFUS of the thalamus for medication-resistant tremor of PD can be considered only within registries, and unilateral MRgFUS of the pallidum is not recommended. CONCLUSIONS: Evidence for invasive therapies in PD is heterogeneous. Only some of these therapies have a strong scientific basis. They differ in their profile of effects and have been tested only for specific patient groups. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
650    _2
$a apomorfin $x terapeutické užití $7 D001058
650    12
$a hluboká mozková stimulace $x metody $7 D046690
650    _2
$a lidé $7 D006801
650    12
$a neurologie $7 D009462
650    12
$a Parkinsonova nemoc $x farmakoterapie $7 D010300
650    _2
$a kvalita života $7 D011788
650    _2
$a tremor $x terapie $7 D014202
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Antonini, Angelo $u Parkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy $1 https://orcid.org/0000000310402807
700    1_
$a Costa, Joao $u Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
700    1_
$a Śmiłowska, Katarzyna $u Department of Neurology, UKSH-Kiel Campus, Christian-Albrechts-University, Kiel, Germany $1 https://orcid.org/0000000191671624
700    1_
$a Berg, Daniela $u Department of Neurology, UKSH-Kiel Campus, Christian-Albrechts-University, Kiel, Germany
700    1_
$a Corvol, Jean-Christophe $u Institut du Cerveau-Paris Brain Institute, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Department of Neurology, Centre d'Investigation Clinique Neurosciences, Sorbonne Université, Paris, France $1 https://orcid.org/0000000173250199
700    1_
$a Fabbrini, Giovanni $u Department Human Neurosciences, Sapienza University of Rome, Rome, Italy $u IRCCS Neuromed, Rome, Italy
700    1_
$a Ferreira, Joaquim $u Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal $u Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal $u Campus Neurológico, Torres Vedras, Portugal $1 https://orcid.org/0000000339505113
700    1_
$a Foltynie, Tom $u Department of Clinical & Movement Neurosciences, Institute of Neurology, London, UK $1 https://orcid.org/0000000307521813
700    1_
$a Mir, Pablo $u Unidad de Trastornos del Movimiento Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Seville, Spain $u Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, Spain $u Departamento de Medicina Facultad de Medicina, Universidad de Sevilla, Seville, Spain $1 https://orcid.org/000000031656302X
700    1_
$a Schrag, Annette $u Institute of Neurology, University Clinic London, London, UK $1 https://orcid.org/0000000298726680
700    1_
$a Seppi, Klaus $u Klinik f. Neurologie, Medizinische Universität Innsbruck, Innsbruck, Austria $1 https://orcid.org/0000000165031455
700    1_
$a Taba, Pille $u Department of Neurology and Neurosurgery, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia $u Tartu University Hospital, Tartu, Estonia
700    1_
$a Ruzicka, Evzen $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia
700    1_
$a Selikhova, Marianna $u Southmead Hospital, Bristol Brain Centre, Bristol, UK, BS10 5NB
700    1_
$a Henschke, Nicholas $u Cochrane Response, London, UK
700    1_
$a Villanueva, Gemma $u Cochrane Response, London, UK
700    1_
$a Moro, Elena $u Division of Neurology, Grenoble, Grenoble Institute of Neurosciences, Grenoble Alpes University, Grenoble, France
773    0_
$w MED00003420 $t Movement disorders $x 1531-8257 $g Roč. 37, č. 7 (2022), s. 1360-1374
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35791767 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100817 $b ABA008
999    __
$a ok $b bmc $g 1854860 $s 1176642
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 37 $c 7 $d 1360-1374 $e 20220706 $i 1531-8257 $m Movement disorders $n Mov Disord $x MED00003420
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace